Reactions 1680, p34 - 2 Dec 2017 Mogamulizumab-induced cutaneous adverse reactions: 6 case reports In a study involving medical review of 25 patients, six patients (3 women and 3 men) aged 44–67 years developed cutaneous adverse reactions during treatment with mogamulizumab. Of these, four patients also received cefepime, cefozopran or piperacillin/tazobactam, which also contributed to the development of mogamulizumab-induced cutaneous adverse reactions (MCARs) [dosages and routes not stated; not all outcomes stated]. All the six patients, who were diagnosed with adult T-cell leukaemia/lymphoma, received treatment with mogamulizumab. After 22–129 days, and after 2-8 cycles of the mogamulizumab therapy, the patients developed grade 2–3 MCARs. Before onsets of MCARs, four out of these six patients started receiving antibacterial therapy with cefepime (2 patients), cefepime and piperacillin/tazobactam (1 patient) and cefozopran (1 patient) for febrile neutropenia. Within two days after the initiation of the antibacterial therapy, the patients developed MCARs. Subsequent immunohistochemical studies of the biopsy specimens revealed multiple CD8+T-cells. The patients were treated with topical/systemic steroids and antihistamines. The mogamulizumab therapy was not discontinued in any of the patient, however, the antibacterial therapy was discontinued in four patients. Within a week after discontinuation of the antibacterial therapy, the skin reaction improved in these four patients. Author comment: "Table 1 summarises the characteristics of 6 patients (25%) who experienced MCARs." "We suspected that drug hypersensitivities were involved in a significant proportion of MCARs." "Given this, the administration of antibiotics was strongly suspected to contribute to MCAR occurrence in 4 patients (cases 2, 3, 4, and 6)." Yasu T, et al. Hypersensitivity reaction to beta-lactam antibiotics in patients with adult t-cell leukemia/lymphoma treated with mogamulizumab. International Journal of Clinical Pharmacology and Therapeutics 55: 807-810, No. 10, Jan 2017. Available from: URL: http://doi.org/10.5414/CP203066 - Japan 803284042 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera